<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1991-08-01" modified="2017-05-10" version="219">
<accession>P22607</accession>
<accession>D3DVP9</accession>
<accession>D3DVQ0</accession>
<accession>Q14308</accession>
<accession>Q16294</accession>
<accession>Q16608</accession>
<accession>Q59FL9</accession>
<name>FGFR3_HUMAN</name>
<protein>
<recommendedName>
<fullName>Fibroblast growth factor receptor 3</fullName>
<shortName>FGFR-3</shortName>
<ecNumber>2.7.10.1</ecNumber>
</recommendedName>
<cdAntigenName>CD333</cdAntigenName>
</protein>
<gene>
<name type="primary">FGFR3</name>
<name type="synonym">JTK4</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1991" name="Proc. Natl. Acad. Sci. U.S.A." volume="88" first="1095" last="1099">
<title>Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.</title>
<authorList>
<person name="Keegan K."/>
<person name="Johnson D.E."/>
<person name="Williams L.T."/>
<person name="Hayman M.J."/>
</authorList>
<dbReference type="PubMed" id="1847508"/>
<dbReference type="DOI" id="10.1073/pnas.88.4.1095"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)</scope>
</reference>
<reference key="2">
<citation type="journal article" date="2001" name="Mol. Cell Biol. Res. Commun." volume="4" first="365" last="373">
<title>Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs.</title>
<authorList>
<person name="Terada M."/>
<person name="Shimizu A."/>
<person name="Sato N."/>
<person name="Miyakaze S.I."/>
<person name="Katayama H."/>
<person name="Kurokawa-Seo M."/>
</authorList>
<dbReference type="PubMed" id="11703096"/>
<dbReference type="DOI" id="10.1006/mcbr.2001.0306"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3)</scope>
<scope>FUNCTION</scope>
<scope>SUBUNIT</scope>
<scope>FGF1- AND FGF2-BINDING</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>GLYCOSYLATION</scope>
<scope>DIMERIZATION</scope>
<source>
<tissue>Squamous cell carcinoma</tissue>
</source>
</reference>
<reference key="3">
<citation type="submission" date="2005-03" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Totoki Y."/>
<person name="Toyoda A."/>
<person name="Takeda T."/>
<person name="Sakaki Y."/>
<person name="Tanaka A."/>
<person name="Yokoyama S."/>
<person name="Ohara O."/>
<person name="Nagase T."/>
<person name="Kikuno R.F."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4)</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="4">
<citation type="submission" date="2004-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NIEHS SNPs program"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA]</scope>
<scope>VARIANTS ARG-65; LEU-384; THR-441; THR-717 AND PHE-726</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2005" name="Nature" volume="434" first="724" last="731">
<title>Generation and annotation of the DNA sequences of human chromosomes 2 and 4.</title>
<authorList>
<person name="Hillier L.W."/>
<person name="Graves T.A."/>
<person name="Fulton R.S."/>
<person name="Fulton L.A."/>
<person name="Pepin K.H."/>
<person name="Minx P."/>
<person name="Wagner-McPherson C."/>
<person name="Layman D."/>
<person name="Wylie K."/>
<person name="Sekhon M."/>
<person name="Becker M.C."/>
<person name="Fewell G.A."/>
<person name="Delehaunty K.D."/>
<person name="Miner T.L."/>
<person name="Nash W.E."/>
<person name="Kremitzki C."/>
<person name="Oddy L."/>
<person name="Du H."/>
<person name="Sun H."/>
<person name="Bradshaw-Cordum H."/>
<person name="Ali J."/>
<person name="Carter J."/>
<person name="Cordes M."/>
<person name="Harris A."/>
<person name="Isak A."/>
<person name="van Brunt A."/>
<person name="Nguyen C."/>
<person name="Du F."/>
<person name="Courtney L."/>
<person name="Kalicki J."/>
<person name="Ozersky P."/>
<person name="Abbott S."/>
<person name="Armstrong J."/>
<person name="Belter E.A."/>
<person name="Caruso L."/>
<person name="Cedroni M."/>
<person name="Cotton M."/>
<person name="Davidson T."/>
<person name="Desai A."/>
<person name="Elliott G."/>
<person name="Erb T."/>
<person name="Fronick C."/>
<person name="Gaige T."/>
<person name="Haakenson W."/>
<person name="Haglund K."/>
<person name="Holmes A."/>
<person name="Harkins R."/>
<person name="Kim K."/>
<person name="Kruchowski S.S."/>
<person name="Strong C.M."/>
<person name="Grewal N."/>
<person name="Goyea E."/>
<person name="Hou S."/>
<person name="Levy A."/>
<person name="Martinka S."/>
<person name="Mead K."/>
<person name="McLellan M.D."/>
<person name="Meyer R."/>
<person name="Randall-Maher J."/>
<person name="Tomlinson C."/>
<person name="Dauphin-Kohlberg S."/>
<person name="Kozlowicz-Reilly A."/>
<person name="Shah N."/>
<person name="Swearengen-Shahid S."/>
<person name="Snider J."/>
<person name="Strong J.T."/>
<person name="Thompson J."/>
<person name="Yoakum M."/>
<person name="Leonard S."/>
<person name="Pearman C."/>
<person name="Trani L."/>
<person name="Radionenko M."/>
<person name="Waligorski J.E."/>
<person name="Wang C."/>
<person name="Rock S.M."/>
<person name="Tin-Wollam A.-M."/>
<person name="Maupin R."/>
<person name="Latreille P."/>
<person name="Wendl M.C."/>
<person name="Yang S.-P."/>
<person name="Pohl C."/>
<person name="Wallis J.W."/>
<person name="Spieth J."/>
<person name="Bieri T.A."/>
<person name="Berkowicz N."/>
<person name="Nelson J.O."/>
<person name="Osborne J."/>
<person name="Ding L."/>
<person name="Meyer R."/>
<person name="Sabo A."/>
<person name="Shotland Y."/>
<person name="Sinha P."/>
<person name="Wohldmann P.E."/>
<person name="Cook L.L."/>
<person name="Hickenbotham M.T."/>
<person name="Eldred J."/>
<person name="Williams D."/>
<person name="Jones T.A."/>
<person name="She X."/>
<person name="Ciccarelli F.D."/>
<person name="Izaurralde E."/>
<person name="Taylor J."/>
<person name="Schmutz J."/>
<person name="Myers R.M."/>
<person name="Cox D.R."/>
<person name="Huang X."/>
<person name="McPherson J.D."/>
<person name="Mardis E.R."/>
<person name="Clifton S.W."/>
<person name="Warren W.C."/>
<person name="Chinwalla A.T."/>
<person name="Eddy S.R."/>
<person name="Marra M.A."/>
<person name="Ovcharenko I."/>
<person name="Furey T.S."/>
<person name="Miller W."/>
<person name="Eichler E.E."/>
<person name="Bork P."/>
<person name="Suyama M."/>
<person name="Torrents D."/>
<person name="Waterston R.H."/>
<person name="Wilson R.K."/>
</authorList>
<dbReference type="PubMed" id="15815621"/>
<dbReference type="DOI" id="10.1038/nature03466"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="6">
<citation type="submission" date="2005-09" db="EMBL/GenBank/DDBJ databases">
<authorList>
<person name="Mural R.J."/>
<person name="Istrail S."/>
<person name="Sutton G.G."/>
<person name="Florea L."/>
<person name="Halpern A.L."/>
<person name="Mobarry C.M."/>
<person name="Lippert R."/>
<person name="Walenz B."/>
<person name="Shatkay H."/>
<person name="Dew I."/>
<person name="Miller J.R."/>
<person name="Flanigan M.J."/>
<person name="Edwards N.J."/>
<person name="Bolanos R."/>
<person name="Fasulo D."/>
<person name="Halldorsson B.V."/>
<person name="Hannenhalli S."/>
<person name="Turner R."/>
<person name="Yooseph S."/>
<person name="Lu F."/>
<person name="Nusskern D.R."/>
<person name="Shue B.C."/>
<person name="Zheng X.H."/>
<person name="Zhong F."/>
<person name="Delcher A.L."/>
<person name="Huson D.H."/>
<person name="Kravitz S.A."/>
<person name="Mouchard L."/>
<person name="Reinert K."/>
<person name="Remington K.A."/>
<person name="Clark A.G."/>
<person name="Waterman M.S."/>
<person name="Eichler E.E."/>
<person name="Adams M.D."/>
<person name="Hunkapiller M.W."/>
<person name="Myers E.W."/>
<person name="Venter J.C."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1991" name="Genomics" volume="11" first="1133" last="1142">
<title>A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4.</title>
<authorList>
<person name="Thompson L.M."/>
<person name="Plummer S."/>
<person name="Schalling M."/>
<person name="Altherr M.R."/>
<person name="Gusella J.F."/>
<person name="Housman D.E."/>
<person name="Wasmuth J.J."/>
</authorList>
<dbReference type="PubMed" id="1664411"/>
<dbReference type="DOI" id="10.1016/0888-7543(91)90041-C"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1)</scope>
<scope>TISSUE SPECIFICITY</scope>
<source>
<tissue>Fetal brain</tissue>
</source>
</reference>
<reference key="8">
<citation type="journal article" date="1990" name="Proc. Natl. Acad. Sci. U.S.A." volume="87" first="8913" last="8917">
<title>Putative tyrosine kinases expressed in K-562 human leukemia cells.</title>
<authorList>
<person name="Partanen J."/>
<person name="Maekelae T.P."/>
<person name="Alitalo R."/>
<person name="Lehvaeslaiho H."/>
<person name="Alitalo K."/>
</authorList>
<dbReference type="PubMed" id="2247464"/>
<dbReference type="DOI" id="10.1073/pnas.87.22.8913"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 614-681</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1994" name="Cancer Res." volume="54" first="5206" last="5211">
<title>Identification of a novel variant form of fibroblast growth factor receptor 3 (FGFR3 IIIb) in human colonic epithelium.</title>
<authorList>
<person name="Murgue B."/>
<person name="Tsunekawa S."/>
<person name="Rosenberg I."/>
<person name="deBeaumont M."/>
<person name="Podolsky D.K."/>
</authorList>
<dbReference type="PubMed" id="7923141"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2)</scope>
<source>
<tissue>Colon tumor</tissue>
</source>
</reference>
<reference key="10">
<citation type="journal article" date="1995" name="Biochim. Biophys. Acta" volume="1264" first="238" last="242">
<title>The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is not strictly tissue-specific.</title>
<authorList>
<person name="Scotet E."/>
<person name="Houssaint E."/>
</authorList>
<dbReference type="PubMed" id="7495869"/>
<dbReference type="DOI" id="10.1016/0167-4781(95)00156-B"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2)</scope>
<source>
<tissue>Keratinocyte</tissue>
</source>
</reference>
<reference key="11">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="15292" last="15297">
<title>Receptor specificity of the fibroblast growth factor family.</title>
<authorList>
<person name="Ornitz D.M."/>
<person name="Xu J."/>
<person name="Colvin J.S."/>
<person name="McEwen D.G."/>
<person name="MacArthur C.A."/>
<person name="Coulier F."/>
<person name="Gao G."/>
<person name="Goldfarb M."/>
</authorList>
<dbReference type="PubMed" id="8663044"/>
<dbReference type="DOI" id="10.1074/jbc.271.25.15292"/>
</citation>
<scope>INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9</scope>
<scope>FUNCTION IN CELL PROLIFERATION</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1999" name="Am. J. Hum. Genet." volume="64" first="722" last="731">
<title>A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene.</title>
<authorList>
<person name="Tavormina P.L."/>
<person name="Bellus G.A."/>
<person name="Webster M.K."/>
<person name="Bamshad M.J."/>
<person name="Fraley A.E."/>
<person name="McIntosh I."/>
<person name="Szabo J."/>
<person name="Jiang W."/>
<person name="Jabs E.W."/>
<person name="Wilcox W.R."/>
<person name="Wasmuth J.J."/>
<person name="Donoghue D.J."/>
<person name="Thompson L.M."/>
<person name="Francomano C.A."/>
</authorList>
<dbReference type="PubMed" id="10053006"/>
<dbReference type="DOI" id="10.1086/302275"/>
</citation>
<scope>INVOLVEMENT IN SADDAN</scope>
<scope>VARIANT SADDAN MET-650</scope>
<scope>CHARACTERIZATION OF VARIANT SADDAN MET-650</scope>
</reference>
<reference key="13">
<citation type="journal article" date="2000" name="Mol. Cell. Biol." volume="20" first="516" last="522">
<title>The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.</title>
<authorList>
<person name="Monsonego-Ornan E."/>
<person name="Adar R."/>
<person name="Feferman T."/>
<person name="Segev O."/>
<person name="Yayon A."/>
</authorList>
<dbReference type="PubMed" id="10611230"/>
<dbReference type="DOI" id="10.1128/MCB.20.2.516-522.2000"/>
</citation>
<scope>FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF SIGNALING PATHWAYS</scope>
<scope>SUBUNIT</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>DEGRADATION</scope>
<scope>AUTOPHOSPHORYLATION</scope>
<scope>CHARACTERIZATION OF VARIANT ACH ARG-380</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2001" name="Mol. Biol. Cell" volume="12" first="931" last="942">
<title>Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.</title>
<authorList>
<person name="Hart K.C."/>
<person name="Robertson S.C."/>
<person name="Donoghue D.J."/>
</authorList>
<dbReference type="PubMed" id="11294897"/>
<dbReference type="DOI" id="10.1091/mbc.12.4.931"/>
</citation>
<scope>FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF PIK3R1; PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES</scope>
<scope>PHOSPHORYLATION AT TYR-724</scope>
<scope>MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770</scope>
<scope>CHARACTERIZATION OF VARIANT GLU-650</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2002" name="FEBS Lett." volume="528" first="83" last="89">
<title>FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation.</title>
<authorList>
<person name="Monsonego-Ornan E."/>
<person name="Adar R."/>
<person name="Rom E."/>
<person name="Yayon A."/>
</authorList>
<dbReference type="PubMed" id="12297284"/>
<dbReference type="DOI" id="10.1016/S0014-5793(02)03255-6"/>
</citation>
<scope>UBIQUITINATION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>MUTAGENESIS OF LYS-508</scope>
<scope>CHARACTERIZATION OF VARIANT ACH ARG-380</scope>
<scope>CHARACTERIZATION OF VARIANT TD2 GLU-650</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2003" name="Oncogene" volume="22" first="6909" last="6918">
<title>The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3.</title>
<authorList>
<person name="Agazie Y.M."/>
<person name="Movilla N."/>
<person name="Ischenko I."/>
<person name="Hayman M.J."/>
</authorList>
<dbReference type="PubMed" id="14534538"/>
<dbReference type="DOI" id="10.1038/sj.onc.1206798"/>
</citation>
<scope>FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL PROLIFERATION</scope>
<scope>FUNCTION IN PHOSPHORYLATION OF FRS2</scope>
<scope>CHARACTERIZATION OF VARIANT GLU-650</scope>
<scope>AUTOPHOSPHORYLATION</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2006" name="J. Biol. Chem." volume="281" first="15694" last="15700">
<title>Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family.</title>
<authorList>
<person name="Zhang X."/>
<person name="Ibrahimi O.A."/>
<person name="Olsen S.K."/>
<person name="Umemori H."/>
<person name="Mohammadi M."/>
<person name="Ornitz D.M."/>
</authorList>
<dbReference type="PubMed" id="16597617"/>
<dbReference type="DOI" id="10.1074/jbc.M601252200"/>
</citation>
<scope>INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20</scope>
<scope>FUNCTION IN STIMULATION OF CELL PROLIFERATION</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2006" name="J. Cell Sci." volume="119" first="380" last="387">
<title>Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling.</title>
<authorList>
<person name="Ben-Zvi T."/>
<person name="Yayon A."/>
<person name="Gertler A."/>
<person name="Monsonego-Ornan E."/>
</authorList>
<dbReference type="PubMed" id="16410555"/>
<dbReference type="DOI" id="10.1242/jcs.02740"/>
</citation>
<scope>INTERACTION WITH SOCS1 AND SOCS3</scope>
<scope>FUNCTION IN ACTIVATION OF STAT1 AND MAP KINASES</scope>
<scope>GLYCOSYLATION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>MUTAGENESIS OF LYS-508</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="19">
<citation type="journal article" date="2007" name="Bone" volume="41" first="273" last="281">
<title>Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.</title>
<authorList>
<person name="Harada D."/>
<person name="Yamanaka Y."/>
<person name="Ueda K."/>
<person name="Nishimura R."/>
<person name="Morishima T."/>
<person name="Seino Y."/>
<person name="Tanaka H."/>
</authorList>
<dbReference type="PubMed" id="17561467"/>
<dbReference type="DOI" id="10.1016/j.bone.2006.11.030"/>
</citation>
<scope>FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION OF PLCG1 AND STAT1</scope>
<scope>INTERACTION WITH FHF1 AND HEPARIN</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>PHOSPHORYLATION</scope>
<scope>CHARACTERIZATION OF VARIANTS ARG-380; GLU-650 AND MET-650</scope>
</reference>
<reference key="20">
<citation type="journal article" date="2007" name="FEBS J." volume="274" first="3078" last="3093">
<title>The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.</title>
<authorList>
<person name="Bonaventure J."/>
<person name="Horne W.C."/>
<person name="Baron R."/>
</authorList>
<dbReference type="PubMed" id="17509076"/>
<dbReference type="DOI" id="10.1111/j.1742-4658.2007.05835.x"/>
</citation>
<scope>FUNCTION IN PHOSPHORYLATION OF CBL</scope>
<scope>UBIQUITINATION</scope>
<scope>GLYCOSYLATION</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>ENZYME REGULATION</scope>
<scope>CHARACTERIZATION OF VARIANTS CYS-248; CYS-373 AND MET-650</scope>
</reference>
<reference key="21">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="2929" last="2936">
<title>Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins.</title>
<authorList>
<person name="Krejci P."/>
<person name="Masri B."/>
<person name="Salazar L."/>
<person name="Farrington-Rock C."/>
<person name="Prats H."/>
<person name="Thompson L.M."/>
<person name="Wilcox W.R."/>
</authorList>
<dbReference type="PubMed" id="17145761"/>
<dbReference type="DOI" id="10.1074/jbc.M606144200"/>
</citation>
<scope>FUNCTION IN PHOSPHORYLATION OF FRS2</scope>
<scope>CHARACTERIZATION OF VARIANT GLU-650</scope>
<scope>ENZYME REGULATION</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="22">
<citation type="journal article" date="2007" name="J. Biol. Chem." volume="282" first="26687" last="26695">
<title>Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.</title>
<authorList>
<person name="Kurosu H."/>
<person name="Choi M."/>
<person name="Ogawa Y."/>
<person name="Dickson A.S."/>
<person name="Goetz R."/>
<person name="Eliseenkova A.V."/>
<person name="Mohammadi M."/>
<person name="Rosenblatt K.P."/>
<person name="Kliewer S.A."/>
<person name="Kuro-o M."/>
</authorList>
<dbReference type="PubMed" id="17623664"/>
<dbReference type="DOI" id="10.1074/jbc.M704165200"/>
</citation>
<scope>INTERACTION WITH FGF19; FGF21 AND KLB</scope>
</reference>
<reference key="23">
<citation type="journal article" date="2007" name="J. Cell. Physiol." volume="212" first="148" last="156">
<title>Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus.</title>
<authorList>
<person name="Citores L."/>
<person name="Bai L."/>
<person name="Sorensen V."/>
<person name="Olsnes S."/>
</authorList>
<dbReference type="PubMed" id="17311277"/>
<dbReference type="DOI" id="10.1002/jcp.21014"/>
</citation>
<scope>FUNCTION IN STAT1 PHOSPHORYLATION</scope>
<scope>GLYCOSYLATION</scope>
<scope>PHOSPHORYLATION</scope>
</reference>
<reference key="24">
<citation type="journal article" date="2008" name="PLoS ONE" volume="3" first="E3961" last="E3961">
<title>Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage.</title>
<authorList>
<person name="Krejci P."/>
<person name="Salazar L."/>
<person name="Kashiwada T.A."/>
<person name="Chlebova K."/>
<person name="Salasova A."/>
<person name="Thompson L.M."/>
<person name="Bryja V."/>
<person name="Kozubik A."/>
<person name="Wilcox W.R."/>
</authorList>
<dbReference type="PubMed" id="19088846"/>
<dbReference type="DOI" id="10.1371/journal.pone.0003961"/>
</citation>
<scope>FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE MAP KINASE SIGNALING PATHWAY</scope>
</reference>
<reference key="25">
<citation type="journal article" date="2008" name="Proc. Natl. Acad. Sci. U.S.A." volume="105" first="10762" last="10767">
<title>A quantitative atlas of mitotic phosphorylation.</title>
<authorList>
<person name="Dephoure N."/>
<person name="Zhou C."/>
<person name="Villen J."/>
<person name="Beausoleil S.A."/>
<person name="Bakalarski C.E."/>
<person name="Elledge S.J."/>
<person name="Gygi S.P."/>
</authorList>
<dbReference type="PubMed" id="18669648"/>
<dbReference type="DOI" id="10.1073/pnas.0805139105"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Cervix carcinoma</tissue>
</source>
</reference>
<reference key="26">
<citation type="journal article" date="2009" name="Hum. Mol. Genet." volume="18" first="1951" last="1961">
<title>A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.</title>
<authorList>
<person name="Salazar L."/>
<person name="Kashiwada T."/>
<person name="Krejci P."/>
<person name="Muchowski P."/>
<person name="Donoghue D."/>
<person name="Wilcox W.R."/>
<person name="Thompson L.M."/>
</authorList>
<dbReference type="PubMed" id="19286672"/>
<dbReference type="DOI" id="10.1093/hmg/ddp116"/>
</citation>
<scope>FUNCTION</scope>
<scope>INTERACTION WITH PIK3R1 AND PLCG1</scope>
<scope>PHOSPHORYLATION AT TYR-760</scope>
</reference>
<reference key="27">
<citation type="journal article" date="2005" name="Cytokine Growth Factor Rev." volume="16" first="139" last="149">
<title>Cellular signaling by fibroblast growth factor receptors.</title>
<authorList>
<person name="Eswarakumar V.P."/>
<person name="Lax I."/>
<person name="Schlessinger J."/>
</authorList>
<dbReference type="PubMed" id="15863030"/>
<dbReference type="DOI" id="10.1016/j.cytogfr.2005.01.001"/>
</citation>
<scope>REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN DISEASE</scope>
</reference>
<reference key="28">
<citation type="journal article" date="2005" name="Exp. Cell Res." volume="304" first="417" last="431">
<title>Cell responses to FGFR3 signalling: growth, differentiation and apoptosis.</title>
<authorList>
<person name="L'Hote C.G."/>
<person name="Knowles M.A."/>
</authorList>
<dbReference type="PubMed" id="15748888"/>
<dbReference type="DOI" id="10.1016/j.yexcr.2004.11.012"/>
</citation>
<scope>REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN; ROLE IN DISEASE; UBIQUITINATION AND DEGRADATION</scope>
</reference>
<reference key="29">
<citation type="journal article" date="2009" name="J. Bone Miner. Metab." volume="27" first="9" last="15">
<title>FGFR3-related dwarfism and cell signaling.</title>
<authorList>
<person name="Harada D."/>
<person name="Yamanaka Y."/>
<person name="Ueda K."/>
<person name="Tanaka H."/>
<person name="Seino Y."/>
</authorList>
<dbReference type="PubMed" id="19066716"/>
<dbReference type="DOI" id="10.1007/s00774-008-0009-7"/>
</citation>
<scope>REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE</scope>
</reference>
<reference key="30">
<citation type="journal article" date="2010" name="Nat. Rev. Cancer" volume="10" first="116" last="129">
<title>Fibroblast growth factor signalling: from development to cancer.</title>
<authorList>
<person name="Turner N."/>
<person name="Grose R."/>
</authorList>
<dbReference type="PubMed" id="20094046"/>
<dbReference type="DOI" id="10.1038/nrc2780"/>
</citation>
<scope>REVIEW ON FUNCTION IN FGF SIGNALING</scope>
</reference>
<reference key="31">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="260" last="271">
<title>Toward a comprehensive characterization of a human cancer cell phosphoproteome.</title>
<authorList>
<person name="Zhou H."/>
<person name="Di Palma S."/>
<person name="Preisinger C."/>
<person name="Peng M."/>
<person name="Polat A.N."/>
<person name="Heck A.J."/>
<person name="Mohammed S."/>
</authorList>
<dbReference type="PubMed" id="23186163"/>
<dbReference type="DOI" id="10.1021/pr300630k"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Erythroleukemia</tissue>
</source>
</reference>
<reference key="32">
<citation type="journal article" date="2004" name="Proc. Natl. Acad. Sci. U.S.A." volume="101" first="935" last="940">
<title>Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.</title>
<authorList>
<person name="Olsen S.K."/>
<person name="Ibrahimi O.A."/>
<person name="Raucci A."/>
<person name="Zhang F."/>
<person name="Eliseenkova A.V."/>
<person name="Yayon A."/>
<person name="Basilico C."/>
<person name="Linhardt R.J."/>
<person name="Schlessinger J."/>
<person name="Mohammadi M."/>
</authorList>
<dbReference type="PubMed" id="14732692"/>
<dbReference type="DOI" id="10.1073/pnas.0307287101"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1</scope>
<scope>ENZYME REGULATION</scope>
<scope>DOMAIN</scope>
</reference>
<reference key="33">
<citation type="journal article" date="1994" name="Nature" volume="371" first="252" last="254">
<title>Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.</title>
<authorList>
<person name="Rousseau F."/>
<person name="Bonaventure J."/>
<person name="Legeai-Mallet L."/>
<person name="Pelet A."/>
<person name="Rozet J.-M."/>
<person name="Maroteaux P."/>
<person name="le Merrer M."/>
<person name="Munnich A."/>
</authorList>
<dbReference type="PubMed" id="8078586"/>
<dbReference type="DOI" id="10.1038/371252a0"/>
</citation>
<scope>VARIANT ACH ARG-380</scope>
</reference>
<reference key="34">
<citation type="journal article" date="1995" name="Am. J. Hum. Genet." volume="56" first="368" last="373">
<title>Achondroplasia is defined by recurrent G380R mutations of FGFR3.</title>
<authorList>
<person name="Bellus G.A."/>
<person name="Hefferon T.W."/>
<person name="de Luna R.I."/>
<person name="Hecht J.T."/>
<person name="Horton W.A."/>
<person name="Machado M."/>
<person name="Kaitila I."/>
<person name="McIntosh I."/>
<person name="Francomano C.A."/>
</authorList>
<dbReference type="PubMed" id="7847369"/>
</citation>
<scope>VARIANT ACH ARG-380</scope>
</reference>
<reference key="35">
<citation type="journal article" date="1995" name="Eur. J. Pediatr." volume="154" first="215" last="219">
<title>A glycine 375-to-cysteine substitution in the transmembrane domain of the fibroblast growth factor receptor-3 in a newborn with achondroplasia.</title>
<authorList>
<person name="Superti-Furga A."/>
<person name="Eich G."/>
<person name="Bucher H.U."/>
<person name="Wisser J."/>
<person name="Giedion A."/>
<person name="Gitzelmann R."/>
<person name="Steinmann B."/>
</authorList>
<dbReference type="PubMed" id="7758520"/>
<dbReference type="DOI" id="10.1007/BF01954274"/>
</citation>
<scope>VARIANT ACH CYS-375</scope>
</reference>
<reference key="36">
<citation type="journal article" date="1995" name="Hum. Mol. Genet." volume="4" first="2175" last="2177">
<title>Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I.</title>
<authorList>
<person name="Tavormina P.L."/>
<person name="Rimoin D.L."/>
<person name="Cohn D.H."/>
<person name="Zhu Y.-Z."/>
<person name="Shiang R."/>
<person name="Wasmuth J.J."/>
</authorList>
<dbReference type="PubMed" id="8589699"/>
<dbReference type="DOI" id="10.1093/hmg/4.11.2175"/>
</citation>
<scope>VARIANT TD1 CYS-249</scope>
</reference>
<reference key="37">
<citation type="journal article" date="1995" name="Nat. Genet." volume="9" first="321" last="328">
<title>Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.</title>
<authorList>
<person name="Tavormina P.L."/>
<person name="Shiang R."/>
<person name="Thompson L.M."/>
<person name="Zhu Y.-Z."/>
<person name="Wilkin D.J."/>
<person name="Lachman R.S."/>
<person name="Wilcox W.R."/>
<person name="Rimoin D.L."/>
<person name="Cohn D.H."/>
<person name="Wasmuth J.J."/>
</authorList>
<dbReference type="PubMed" id="7773297"/>
<dbReference type="DOI" id="10.1038/ng0395-321"/>
</citation>
<scope>VARIANTS TD1 CYS-248 AND CYS-371</scope>
<scope>VARIANT TD2 GLU-650</scope>
</reference>
<reference key="38">
<citation type="journal article" date="1995" name="Nat. Genet." volume="10" first="357" last="359">
<title>A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia.</title>
<authorList>
<person name="Bellus G.A."/>
<person name="McIntosh I."/>
<person name="Smith E.A."/>
<person name="Aylsworth A.S."/>
<person name="Kaitila I."/>
<person name="Horton W.A."/>
<person name="Greenhaw G.A."/>
<person name="Hecht J.T."/>
<person name="Francomano C.A."/>
</authorList>
<dbReference type="PubMed" id="7670477"/>
<dbReference type="DOI" id="10.1038/ng0795-357"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA LYS-540</scope>
</reference>
<reference key="39">
<citation type="journal article" date="1995" name="Nat. Genet." volume="11" first="462" last="464">
<title>Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans.</title>
<authorList>
<person name="Meyers G.A."/>
<person name="Orlow S.J."/>
<person name="Munro I.R."/>
<person name="Przylepa K.A."/>
<person name="Jabs E.W."/>
</authorList>
<dbReference type="PubMed" id="7493034"/>
<dbReference type="DOI" id="10.1038/ng1295-462"/>
</citation>
<scope>VARIANT CAN GLU-391</scope>
</reference>
<reference key="40">
<citation type="journal article" date="1996" name="EMBO J." volume="15" first="520" last="527">
<title>Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.</title>
<authorList>
<person name="Webster M.K."/>
<person name="Donoghue D.J."/>
</authorList>
<dbReference type="PubMed" id="8599935"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT ACH ARG-380</scope>
</reference>
<reference key="41">
<citation type="journal article" date="1996" name="Hum. Mol. Genet." volume="5" first="509" last="512">
<title>Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).</title>
<authorList>
<person name="Rousseau F."/>
<person name="el Ghouzzi V."/>
<person name="Delezoide A.-L."/>
<person name="Legeai-Mallet L."/>
<person name="le Merrer M."/>
<person name="Munnich A."/>
<person name="Bonaventure J."/>
</authorList>
<dbReference type="PubMed" id="8845844"/>
<dbReference type="DOI" id="10.1093/hmg/5.4.509"/>
</citation>
<scope>VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373</scope>
</reference>
<reference key="42">
<citation type="journal article" date="1996" name="Mol. Cell. Biol." volume="16" first="4081" last="4087">
<title>Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.</title>
<authorList>
<person name="Webster M.K."/>
<person name="D'Avis P.Y."/>
<person name="Robertson S.C."/>
<person name="Donoghue D.J."/>
</authorList>
<dbReference type="PubMed" id="8754806"/>
<dbReference type="DOI" id="10.1128/MCB.16.8.4081"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT TD2 GLU-650</scope>
<scope>CHARACTERIZATION OF VARIANT GLN-650</scope>
<scope>PHOSPHORYLATION AT TYR-647 AND TYR-648</scope>
</reference>
<reference key="43">
<citation type="journal article" date="1997" name="Am. J. Hum. Genet." volume="60" first="555" last="564">
<title>A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome.</title>
<authorList>
<person name="Muenke M."/>
<person name="Gripp K.W."/>
<person name="McDonald-Mcginn D.M."/>
<person name="Gaudenz K."/>
<person name="Whitaker L.A."/>
<person name="Bartlett S.P."/>
<person name="Markowitz R.I."/>
<person name="Robin N.H."/>
<person name="Nwokoro N."/>
<person name="Mulvihill J.J."/>
<person name="Losken H.W."/>
<person name="Mulliken J.B."/>
<person name="Guttmacher A.E."/>
<person name="Wilroy R.S."/>
<person name="Clarke L.A."/>
<person name="Hollway G."/>
<person name="Ades L.C."/>
<person name="Haan E.A."/>
<person name="Mulley J.C."/>
<person name="Cohen M.M. Jr."/>
<person name="Bellus G.A."/>
<person name="Francomano C.A."/>
<person name="Moloney D.M."/>
<person name="Wall S.A."/>
<person name="Wilkie A.O.M."/>
<person name="Zackai E.H."/>
</authorList>
<dbReference type="PubMed" id="9042914"/>
</citation>
<scope>VARIANT MNKS ARG-250</scope>
</reference>
<reference key="44">
<citation type="journal article" date="1997" name="Nat. Genet." volume="16" first="260" last="264">
<title>Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.</title>
<authorList>
<person name="Chesi M."/>
<person name="Nardini E."/>
<person name="Brents L.A."/>
<person name="Schroeck E."/>
<person name="Ried T."/>
<person name="Kuehl W.M."/>
<person name="Bergsagel P.L."/>
</authorList>
<dbReference type="PubMed" id="9207791"/>
<dbReference type="DOI" id="10.1038/ng0797-260"/>
</citation>
<scope>INVOLVEMENT IN MULTIPLE MYELOMA</scope>
<scope>VARIANTS CYS-373; GLU-650 AND MET-650</scope>
</reference>
<reference key="45">
<citation type="journal article" date="1998" name="Endocr. J." volume="45" first="S171" last="S174">
<title>G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric dysplasia.</title>
<authorList>
<person name="Katsumata N."/>
<person name="Kuno T."/>
<person name="Miyazaki S."/>
<person name="Mikami S."/>
<person name="Nagashima-Miyokawa A."/>
<person name="Nimura A."/>
<person name="Horikawa R."/>
<person name="Tanaka T."/>
</authorList>
<dbReference type="PubMed" id="9790257"/>
<dbReference type="DOI" id="10.1507/endocrj.45.Suppl_S171"/>
</citation>
<scope>VARIANT TD1 CYS-370</scope>
</reference>
<reference key="46">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="11" first="333" last="333">
<title>A novel missense mutation Ile538Val in the fibroblast growth factor receptor 3 in hypochondroplasia.</title>
<authorList>
<person name="Grigelioniene G."/>
<person name="Hagenaes L."/>
<person name="Ekloef O."/>
<person name="Neumeyer L."/>
<person name="Haereid P.E."/>
<person name="Anvret M."/>
</authorList>
<dbReference type="PubMed" id="10215410"/>
<dbReference type="DOI" id="10.1002/(SICI)1098-1004(1998)11:4&lt;333::AID-HUMU17>3.0.CO;2-J"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA VAL-538</scope>
</reference>
<reference key="47">
<citation type="journal article" date="1998" name="Hum. Mutat. Suppl." volume="1" first="S62" last="S65">
<title>Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia.</title>
<authorList>
<person name="Deutz-Terlouw P.P."/>
<person name="Losekoot M."/>
<person name="Aalfs C.M."/>
<person name="Hennekam R.C.M."/>
<person name="Bakker E."/>
</authorList>
<dbReference type="PubMed" id="9452043"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA THR-540</scope>
</reference>
<reference key="48">
<citation type="journal article" date="1998" name="Hum. Mutat." volume="12" first="362" last="363">
<title>Lys650Met substitution in the tyrosine kinase domain of the fibroblast growth factor receptor gene causes thanatophoric dysplasia type I.</title>
<authorList>
<person name="Kitoh H."/>
<person name="Brodie S.G."/>
<person name="Kupke K.G."/>
<person name="Lachman R.S."/>
<person name="Wilcox W.R."/>
</authorList>
<dbReference type="PubMed" id="10671061"/>
</citation>
<scope>VARIANT TD1 MET-650</scope>
</reference>
<reference key="49">
<citation type="journal article" date="1998" name="Lancet" volume="351" first="877" last="878">
<title>Deafness due to Pro250Arg mutation of FGFR3.</title>
<authorList>
<person name="Hollway G.E."/>
<person name="Suthers G.K."/>
<person name="Battese K.M."/>
<person name="Turner A.M."/>
<person name="David D.J."/>
<person name="Mulley J.C."/>
</authorList>
<dbReference type="PubMed" id="9525367"/>
<dbReference type="DOI" id="10.1016/S0140-6736(98)24012-8"/>
</citation>
<scope>VARIANT ARG-250</scope>
</reference>
<reference key="50">
<citation type="journal article" date="1999" name="Am. J. Med. Genet." volume="84" first="476" last="480">
<title>Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations.</title>
<authorList>
<person name="Brodie S.G."/>
<person name="Kitoh H."/>
<person name="Lachman R.S."/>
<person name="Nolasco L.M."/>
<person name="Mekikian P.B."/>
<person name="Wilcox W.R."/>
</authorList>
<dbReference type="PubMed" id="10360402"/>
<dbReference type="DOI" id="10.1002/(SICI)1096-8628(19990611)84:5&lt;476::AID-AJMG12>3.3.CO;2-O"/>
</citation>
<scope>VARIANTS TD1 CYS-248; CYS-249 AND CYS-373</scope>
</reference>
<reference key="51">
<citation type="journal article" date="1999" name="J. Med. Genet." volume="36" first="9" last="13">
<title>Sex related expressivity of the phenotype in coronal craniosynostosis caused by the recurrent P250R FGFR3 mutation.</title>
<authorList>
<person name="Lajeunie E."/>
<person name="El Ghouzzi V."/>
<person name="Le Merrer M."/>
<person name="Munnich A."/>
<person name="Bonaventure J."/>
<person name="Renier D."/>
</authorList>
<dbReference type="PubMed" id="9950359"/>
</citation>
<scope>VARIANT MNKS ARG-250</scope>
</reference>
<reference key="52">
<citation type="journal article" date="1999" name="Nat. Genet." volume="23" first="18" last="20">
<title>Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.</title>
<authorList>
<person name="Cappellen D."/>
<person name="De Oliveira C."/>
<person name="Ricol D."/>
<person name="Gil Diez de Medina S."/>
<person name="Bourdin J."/>
<person name="Sastre-Garau X."/>
<person name="Chopin D."/>
<person name="Thiery J.P."/>
<person name="Radvanyi F."/>
</authorList>
<dbReference type="PubMed" id="10471491"/>
<dbReference type="DOI" id="10.1038/12615"/>
</citation>
<scope>VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650</scope>
<scope>VARIANTS CERCA CYS-248; CYS-249; CYS-370 AND GLU-650</scope>
</reference>
<reference key="53">
<citation type="journal article" date="2000" name="Am. J. Hum. Genet." volume="67" first="1411" last="1421">
<title>Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.</title>
<authorList>
<person name="Bellus G.A."/>
<person name="Spector E.B."/>
<person name="Speiser P.W."/>
<person name="Weaver C.A."/>
<person name="Garber A.T."/>
<person name="Bryke C.R."/>
<person name="Israel J."/>
<person name="Rosengren S.S."/>
<person name="Webster M.K."/>
<person name="Donoghue D.J."/>
<person name="Francomano C.A."/>
</authorList>
<dbReference type="PubMed" id="11055896"/>
<dbReference type="DOI" id="10.1086/316892"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA GLN-650</scope>
</reference>
<reference key="54">
<citation type="journal article" date="2000" name="J. Med. Genet." volume="37" first="220" last="224">
<title>Clinical and radiographic features of a family with hypochondroplasia owing to a novel asn540ser mutation in the fibroblast growth factor receptor 3 gene.</title>
<authorList>
<person name="Mortier G."/>
<person name="Nuytinck L."/>
<person name="Craen M."/>
<person name="Renard J.-P."/>
<person name="Leroy J.G."/>
<person name="De Paepe A."/>
</authorList>
<dbReference type="PubMed" id="10777366"/>
<dbReference type="DOI" id="10.1136/jmg.37.3.220"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA SER-540</scope>
</reference>
<reference key="55">
<citation type="journal article" date="2001" name="Am. J. Med. Genet." volume="104" first="112" last="119">
<title>Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel shoulder with and without Pro250Arg mutation in the FGFR3 gene.</title>
<authorList>
<person name="Lowry R.B."/>
<person name="Jabs E.W."/>
<person name="Graham G.E."/>
<person name="Gerritsen J."/>
<person name="Fleming J."/>
</authorList>
<dbReference type="PubMed" id="11746040"/>
<dbReference type="DOI" id="10.1002/ajmg.10049"/>
</citation>
<scope>VARIANT MNKS ARG-250</scope>
</reference>
<reference key="56">
<citation type="journal article" date="2001" name="Br. J. Haematol." volume="114" first="362" last="364">
<title>Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).</title>
<authorList>
<person name="Intini D."/>
<person name="Baldini L."/>
<person name="Fabris S."/>
<person name="Lombardi L."/>
<person name="Ciceri G."/>
<person name="Maiolo A.T."/>
<person name="Neri A."/>
</authorList>
<dbReference type="PubMed" id="11529856"/>
<dbReference type="DOI" id="10.1046/j.1365-2141.2001.02957.x"/>
</citation>
<scope>INVOLVEMENT IN MULTIPLE MYELOMA</scope>
<scope>VARIANT CYS-248</scope>
</reference>
<reference key="57">
<citation type="journal article" date="2001" name="Cancer Res." volume="61" first="3541" last="3543">
<title>Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.</title>
<authorList>
<person name="Jang J.-H."/>
<person name="Shin K.-H."/>
<person name="Park J.-G."/>
</authorList>
<dbReference type="PubMed" id="11325814"/>
</citation>
<scope>VARIANT COLORECTAL CANCER LYS-322</scope>
</reference>
<reference key="58">
<citation type="journal article" date="2001" name="Oncogene" volume="20" first="686" last="691">
<title>Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.</title>
<authorList>
<person name="Sibley K."/>
<person name="Cuthbert-Heavens D."/>
<person name="Knowles M.A."/>
</authorList>
<dbReference type="PubMed" id="11314002"/>
<dbReference type="DOI" id="10.1038/sj.onc.1204110"/>
</citation>
<scope>VARIANT BLC CANCER GLN-650</scope>
</reference>
<reference key="59">
<citation type="journal article" date="2003" name="Am. J. Med. Genet. A" volume="119" first="81" last="84">
<title>Hypochondroplasia and stature within normal limits: another family with an Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene.</title>
<authorList>
<person name="Thauvin-Robinet C."/>
<person name="Faivre L."/>
<person name="Lewin P."/>
<person name="De Monleon J.-V."/>
<person name="Francois C."/>
<person name="Huet F."/>
<person name="Couailler J.-F."/>
<person name="Campos-Xavier A.B."/>
<person name="Bonaventure J."/>
<person name="Le Merrer M."/>
</authorList>
<dbReference type="PubMed" id="12707965"/>
<dbReference type="DOI" id="10.1002/ajmg.a.10238"/>
</citation>
<scope>VARIANT HYPOCHONDROPLASIA SER-540</scope>
</reference>
<reference key="60">
<citation type="journal article" date="2005" name="Hum. Mol. Genet." volume="14" first="1153" last="1160">
<title>Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.</title>
<authorList>
<person name="Logie A."/>
<person name="Dunois-Larde C."/>
<person name="Rosty C."/>
<person name="Levrel O."/>
<person name="Blanche M."/>
<person name="Ribeiro A."/>
<person name="Gasc J.-M."/>
<person name="Jorcano J."/>
<person name="Werner S."/>
<person name="Sastre-Garau X."/>
<person name="Thiery J.P."/>
<person name="Radvanyi F."/>
</authorList>
<dbReference type="PubMed" id="15772091"/>
<dbReference type="DOI" id="10.1093/hmg/ddi127"/>
</citation>
<scope>VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650 AND MET-650</scope>
</reference>
<reference key="61">
<citation type="journal article" date="2006" name="Am. J. Hum. Genet." volume="79" first="935" last="941">
<title>A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing loss (CATSHL) syndrome.</title>
<authorList>
<person name="Toydemir R.M."/>
<person name="Brassington A.E."/>
<person name="Bayrak-Toydemir P."/>
<person name="Krakowiak P.A."/>
<person name="Jorde L.B."/>
<person name="Whitby F.G."/>
<person name="Longo N."/>
<person name="Viskochil D.H."/>
<person name="Carey J.C."/>
<person name="Bamshad M.J."/>
</authorList>
<dbReference type="PubMed" id="17033969"/>
<dbReference type="DOI" id="10.1086/508433"/>
</citation>
<scope>VARIANT CATSHLS HIS-621</scope>
</reference>
<reference key="62">
<citation type="journal article" date="2006" name="J. Clin. Invest." volume="116" first="2201" last="2207">
<title>Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.</title>
<authorList>
<person name="Hafner C."/>
<person name="van Oers J.M.M."/>
<person name="Vogt T."/>
<person name="Landthaler M."/>
<person name="Stoehr R."/>
<person name="Blaszyk H."/>
<person name="Hofstaedter F."/>
<person name="Zwarthoff E.C."/>
<person name="Hartmann A."/>
</authorList>
<dbReference type="PubMed" id="16841094"/>
<dbReference type="DOI" id="10.1172/JCI28163"/>
</citation>
<scope>VARIANTS KNEN CYS-248; CYS-370 AND ARG-380</scope>
</reference>
<reference key="63">
<citation type="journal article" date="2006" name="Nat. Genet." volume="38" first="414" last="417">
<title>Mutations in different components of FGF signaling in LADD syndrome.</title>
<authorList>
<person name="Rohmann E."/>
<person name="Brunner H.G."/>
<person name="Kayserili H."/>
<person name="Uyguner O."/>
<person name="Nuernberg G."/>
<person name="Lew E.D."/>
<person name="Dobbie A."/>
<person name="Eswarakumar V.P."/>
<person name="Uzumcu A."/>
<person name="Ulubil-Emeroglu M."/>
<person name="Leroy J.G."/>
<person name="Li Y."/>
<person name="Becker C."/>
<person name="Lehnerdt K."/>
<person name="Cremers C.W.R.J."/>
<person name="Yueksel-Apak M."/>
<person name="Nuernberg P."/>
<person name="Kubisch C."/>
<person name="Schlessinger J."/>
<person name="van Bokhoven H."/>
<person name="Wollnik B."/>
</authorList>
<dbReference type="PubMed" id="16501574"/>
<dbReference type="DOI" id="10.1038/ng1757"/>
</citation>
<scope>VARIANT LADDS ASN-513</scope>
</reference>
<reference key="64">
<citation type="journal article" date="2007" name="Clin. Genet." volume="72" first="405" last="410">
<title>Crouzon with acanthosis nigricans. Further delineation of the syndrome.</title>
<authorList>
<person name="Arnaud-Lopez L."/>
<person name="Fragoso R."/>
<person name="Mantilla-Capacho J."/>
<person name="Barros-Nunez P."/>
</authorList>
<dbReference type="PubMed" id="17935505"/>
<dbReference type="DOI" id="10.1111/j.1399-0004.2007.00884.x"/>
</citation>
<scope>VARIANT CAN GLU-391</scope>
</reference>
<reference key="65">
<citation type="journal article" date="2007" name="Nature" volume="446" first="153" last="158">
<title>Patterns of somatic mutation in human cancer genomes.</title>
<authorList>
<person name="Greenman C."/>
<person name="Stephens P."/>
<person name="Smith R."/>
<person name="Dalgliesh G.L."/>
<person name="Hunter C."/>
<person name="Bignell G."/>
<person name="Davies H."/>
<person name="Teague J."/>
<person name="Butler A."/>
<person name="Stevens C."/>
<person name="Edkins S."/>
<person name="O'Meara S."/>
<person name="Vastrik I."/>
<person name="Schmidt E.E."/>
<person name="Avis T."/>
<person name="Barthorpe S."/>
<person name="Bhamra G."/>
<person name="Buck G."/>
<person name="Choudhury B."/>
<person name="Clements J."/>
<person name="Cole J."/>
<person name="Dicks E."/>
<person name="Forbes S."/>
<person name="Gray K."/>
<person name="Halliday K."/>
<person name="Harrison R."/>
<person name="Hills K."/>
<person name="Hinton J."/>
<person name="Jenkinson A."/>
<person name="Jones D."/>
<person name="Menzies A."/>
<person name="Mironenko T."/>
<person name="Perry J."/>
<person name="Raine K."/>
<person name="Richardson D."/>
<person name="Shepherd R."/>
<person name="Small A."/>
<person name="Tofts C."/>
<person name="Varian J."/>
<person name="Webb T."/>
<person name="West S."/>
<person name="Widaa S."/>
<person name="Yates A."/>
<person name="Cahill D.P."/>
<person name="Louis D.N."/>
<person name="Goldstraw P."/>
<person name="Nicholson A.G."/>
<person name="Brasseur F."/>
<person name="Looijenga L."/>
<person name="Weber B.L."/>
<person name="Chiew Y.-E."/>
<person name="DeFazio A."/>
<person name="Greaves M.F."/>
<person name="Green A.R."/>
<person name="Campbell P."/>
<person name="Birney E."/>
<person name="Easton D.F."/>
<person name="Chenevix-Trench G."/>
<person name="Tan M.-H."/>
<person name="Khoo S.K."/>
<person name="Teh B.T."/>
<person name="Yuen S.T."/>
<person name="Leung S.Y."/>
<person name="Wooster R."/>
<person name="Futreal P.A."/>
<person name="Stratton M.R."/>
</authorList>
<dbReference type="PubMed" id="17344846"/>
<dbReference type="DOI" id="10.1038/nature05610"/>
</citation>
<scope>VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646 AND GLU-650</scope>
</reference>
<reference key="66">
<citation type="journal article" date="2009" name="Nat. Genet." volume="41" first="1247" last="1252">
<title>Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.</title>
<authorList>
<person name="Goriely A."/>
<person name="Hansen R.M."/>
<person name="Taylor I.B."/>
<person name="Olesen I.A."/>
<person name="Jacobsen G.K."/>
<person name="McGowan S.J."/>
<person name="Pfeifer S.P."/>
<person name="McVean G.A."/>
<person name="Rajpert-De Meyts E."/>
<person name="Wilkie A.O."/>
</authorList>
<dbReference type="PubMed" id="19855393"/>
<dbReference type="DOI" id="10.1038/ng.470"/>
</citation>
<scope>VARIANT TGCT GLU-650</scope>
</reference>
<comment type="function">
<text evidence="14 18 22 26 29 31 35 36 38 39 42 43 53">Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but can also promote cancer cell proliferation. Required for normal development of the inner ear. Phosphorylates PLCG1, CBL and FRS2. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Plays a role in the regulation of vitamin D metabolism. Mutations that lead to constitutive kinase activation or impair normal FGFR3 maturation, internalization and degradation lead to aberrant signaling. Over-expressed or constitutively activated FGFR3 promotes activation of PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its capacity to bind FGF1 and FGF2 and hence may interfere with FGF signaling.</text>
</comment>
<comment type="catalytic activity">
<text evidence="9 24 35">ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.</text>
</comment>
<comment type="enzyme regulation">
<text evidence="27 35 38">Present in an inactive conformation in the absence of bound ligand. Ligand binding leads to dimerization and activation by autophosphorylation on tyrosine residues. Inhibited by SU5402.</text>
</comment>
<comment type="subunit">
<text evidence="14 22 27 29 31 39 40 43 53">Monomer. Homodimer after ligand binding. Interacts with FGF1, FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19, FGF20 and FGF23 (in vitro). Interacts with KLB. Affinity for fibroblast growth factors (FGFs) is increased by heparan sulfate glycosaminoglycans that function as coreceptors. Likewise, KLB increases the affinity for FGF19 and FGF21. Interacts with PIK3R1, PLCG1, SOCS1 and SOCS3. Isoform 3 forms disulfide-linked dimers.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-348399"/>
<interactant intactId="EBI-698068">
<id>P05230</id>
<label>FGF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-348399"/>
<interactant intactId="EBI-352572">
<id>P08238</id>
<label>HSP90AB1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="subcellular location">
<molecule>Isoform 1</molecule>
<subcellularLocation>
<location>Cell membrane</location>
<topology>Single-pass type I membrane protein</topology>
</subcellularLocation>
<subcellularLocation>
<location>Cytoplasmic vesicle</location>
</subcellularLocation>
<subcellularLocation>
<location>Endoplasmic reticulum</location>
</subcellularLocation>
<text>The activated receptor is rapidly internalized and degraded. Detected in intracellular vesicles after internalization of the autophosphorylated receptor.</text>
</comment>
<comment type="subcellular location">
<molecule>Isoform 2</molecule>
<subcellularLocation>
<location evidence="4">Cell membrane</location>
<topology evidence="4">Single-pass type I membrane protein</topology>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 3</molecule>
<subcellularLocation>
<location>Secreted</location>
</subcellularLocation>
</comment>
<comment type="subcellular location">
<molecule>Isoform 4</molecule>
<subcellularLocation>
<location evidence="4">Cell membrane</location>
<topology evidence="4">Single-pass type I membrane protein</topology>
</subcellularLocation>
</comment>
<comment type="alternative products">
<event type="alternative splicing"/>
<isoform>
<id>P22607-1</id>
<name>1</name>
<name>IIIc</name>
<sequence type="displayed"/>
</isoform>
<isoform>
<id>P22607-2</id>
<name>2</name>
<name>IIIb</name>
<sequence type="described" ref="VSP_002988"/>
</isoform>
<isoform>
<id>P22607-3</id>
<name>3</name>
<name>FGFR3deltaTM</name>
<sequence type="described" ref="VSP_002989"/>
</isoform>
<isoform>
<id>P22607-4</id>
<name>4</name>
<sequence type="described" ref="VSP_040945"/>
<text>No experimental confirmation available.</text>
</isoform>
</comment>
<comment type="tissue specificity">
<text evidence="32">Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isoform 2 is detected in epithelial cells. Isoform 1 is not detected in epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic cells.</text>
</comment>
<comment type="domain">
<text evidence="27">The second and third Ig-like domains directly interact with fibroblast growth factors (FGF) and heparan sulfate proteoglycans.</text>
</comment>
<comment type="PTM">
<text evidence="18 43">Autophosphorylated. Binding of FGF family members together with heparan sulfate proteoglycan or heparin promotes receptor dimerization and autophosphorylation on tyrosine residues. Autophosphorylation occurs in trans between the two FGFR molecules present in the dimer. Phosphorylation at Tyr-724 is essential for stimulation of cell proliferation and activation of PIK3R1, STAT1 and MAP kinase signaling. Phosphorylation at Tyr-760 is required for interaction with PIK3R1 and PLCG1.</text>
</comment>
<comment type="PTM">
<text evidence="24 38">Ubiquitinated. Is rapidly ubiquitinated after ligand binding and autophosphorylation, leading to receptor internalization and degradation. Subject to both proteasomal and lysosomal degradation.</text>
</comment>
<comment type="PTM">
<text evidence="22 29 36 38">N-glycosylated in the endoplasmic reticulum. The N-glycan chains undergo further maturation to an Endo H-resistant form in the Golgi apparatus.</text>
</comment>
<comment type="disease" evidence="14 24 47 49 50 52">
<disease id="DI-00021">
<name>Achondroplasia</name>
<acronym>ACH</acronym>
<description>A frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.</description>
<dbReference type="MIM" id="100800"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="41 45">
<disease id="DI-01453">
<name>Crouzon syndrome with acanthosis nigricans</name>
<acronym>CAN</acronym>
<description>Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.</description>
<dbReference type="MIM" id="612247"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="12 15 48 51 55 60">
<disease id="DI-02363">
<name>Thanatophoric dysplasia 1</name>
<acronym>TD1</acronym>
<description>A neonatal lethal skeletal dysplasia. Affected individuals manifest severe shortening of the limbs with macrocephaly, narrow thorax, short ribs, and curved femurs.</description>
<dbReference type="MIM" id="187600"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="24 48 54">
<disease id="DI-03093">
<name>Thanatophoric dysplasia 2</name>
<acronym>TD2</acronym>
<description>A neonatal lethal skeletal dysplasia causing severe shortening of the limbs, narrow thorax and short ribs. Patients with thanatophoric dysplasia type 2 have straight femurs and cloverleaf skull.</description>
<dbReference type="MIM" id="187601"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="11 16 17 25 46 58">
<disease id="DI-01786">
<name>Hypochondroplasia</name>
<acronym>HCH</acronym>
<description>Autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.</description>
<dbReference type="MIM" id="146000"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="13 19">
<disease id="DI-02612">
<name>Bladder cancer</name>
<acronym>BLC</acronym>
<description>A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.</description>
<dbReference type="MIM" id="109800"/>
</disease>
<text>Disease susceptibility is associated with variations affecting the gene represented in this entry. Somatic mutations can constitutively activate FGFR3.</text>
</comment>
<comment type="disease" evidence="13">
<disease id="DI-02838">
<name>Cervical cancer</name>
<acronym>CERCA</acronym>
<description>A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.</description>
<dbReference type="MIM" id="603956"/>
</disease>
<text>The gene represented in this entry is involved in disease pathogenesis.</text>
</comment>
<comment type="disease" evidence="34">
<disease id="DI-01312">
<name>Camptodactyly, tall stature, and hearing loss syndrome</name>
<acronym>CATSHLS</acronym>
<description>An autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.</description>
<dbReference type="MIM" id="610474"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="21 57">
<disease id="DI-02700">
<name>Multiple myeloma</name>
<acronym>MM</acronym>
<description>A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.</description>
<dbReference type="MIM" id="254500"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis. A chromosomal aberration involving FGFR3 is found in multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.</text>
</comment>
<comment type="disease" evidence="30">
<disease id="DI-00627">
<name>Lacrimo-auriculo-dento-digital syndrome</name>
<acronym>LADDS</acronym>
<description>An autosomal dominant ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. Lacrimo-auriculo-dento-digital syndrome is characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.</description>
<dbReference type="MIM" id="149730"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="33">
<disease id="DI-01860">
<name>Keratinocytic non-epidermolytic nevus</name>
<acronym>KNEN</acronym>
<description>Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.</description>
<dbReference type="MIM" id="162900"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="23 56 61">
<disease id="DI-00784">
<name>Muenke syndrome</name>
<acronym>MNKS</acronym>
<description>A condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.</description>
<dbReference type="MIM" id="602849"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="28">
<disease id="DI-00625">
<name>Keratosis, seborrheic</name>
<acronym>KERSEB</acronym>
<description>A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.</description>
<dbReference type="MIM" id="182000"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="44">
<disease id="DI-02749">
<name>Testicular germ cell tumor</name>
<acronym>TGCT</acronym>
<description>A common malignancy in males representing 95% of all testicular neoplasms. TGCTs have various pathologic subtypes including: unclassified intratubular germ cell neoplasia, seminoma (including cases with syncytiotrophoblastic cells), spermatocytic seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.</description>
<dbReference type="MIM" id="273300"/>
</disease>
<text>The gene represented in this entry may be involved in disease pathogenesis.</text>
</comment>
<comment type="disease" evidence="10">
<disease id="DI-04490">
<name>Achondroplasia, severe, with developmental delay and acanthosis nigricans</name>
<acronym>SADDAN</acronym>
<description>A severe form of achondroplasia associated with developmental delay and acanthosis nigricans. Patients manifest short-limb dwarfism, with a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands. Acanthosis nigricans is a skin condition characterized by brown-pigmented, velvety verrucosities in body folds and creases.</description>
<dbReference type="MIM" id="616482"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="8">Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.</text>
</comment>
<comment type="sequence caution" evidence="66">
<conflict type="erroneous initiation">
<sequence resource="EMBL-CDS" id="BAD92678" version="1"/>
</conflict>
<text>Translation N-terminally shortened.</text>
</comment>
<comment type="online information" name="Atlas of Genetics and Cytogenetics in Oncology and Haematology">
<link uri="http://atlasgeneticsoncology.org/Genes/FGFRID99.html"/>
</comment>
<comment type="online information" name="NIEHS-SNPs">
<link uri="http://egp.gs.washington.edu/data/fgfr3/"/>
</comment>
<dbReference type="EC" id="2.7.10.1"/>
<dbReference type="EMBL" id="M58051">
<property type="protein sequence ID" value="AAA52450.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AF245114">
<property type="protein sequence ID" value="AAF63380.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB209441">
<property type="protein sequence ID" value="BAD92678.1"/>
<property type="status" value="ALT_INIT"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AY768549">
<property type="protein sequence ID" value="AAU89726.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AC016773">
<property type="status" value="NOT_ANNOTATED_CDS"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471131">
<property type="protein sequence ID" value="EAW82564.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471131">
<property type="protein sequence ID" value="EAW82565.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471131">
<property type="protein sequence ID" value="EAW82566.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="CH471131">
<property type="protein sequence ID" value="EAW82567.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="M64347">
<property type="protein sequence ID" value="AAA58470.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M59374">
<property type="protein sequence ID" value="AAA63209.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="S76733">
<property type="protein sequence ID" value="AAB33323.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="X84939">
<property type="protein sequence ID" value="CAA59334.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="U22410">
<property type="protein sequence ID" value="AAA67781.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS3353.1">
<molecule id="P22607-1"/>
</dbReference>
<dbReference type="CCDS" id="CCDS3354.1">
<molecule id="P22607-3"/>
</dbReference>
<dbReference type="CCDS" id="CCDS54706.1">
<molecule id="P22607-2"/>
</dbReference>
<dbReference type="PIR" id="A38576">
<property type="entry name" value="TVHUF3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000133.1">
<molecule id="P22607-1"/>
<property type="nucleotide sequence ID" value="NM_000142.4"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001156685.1">
<molecule id="P22607-2"/>
<property type="nucleotide sequence ID" value="NM_001163213.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_075254.1">
<molecule id="P22607-3"/>
<property type="nucleotide sequence ID" value="NM_022965.3"/>
</dbReference>
<dbReference type="UniGene" id="Hs.1420"/>
<dbReference type="PDB" id="1RY7">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.20"/>
<property type="chains" value="B=33-365"/>
</dbReference>
<dbReference type="PDB" id="2LZL">
<property type="method" value="NMR"/>
<property type="chains" value="A/B=357-399"/>
</dbReference>
<dbReference type="PDB" id="4K33">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.34"/>
<property type="chains" value="A=449-759"/>
</dbReference>
<dbReference type="PDBsum" id="1RY7"/>
<dbReference type="PDBsum" id="2LZL"/>
<dbReference type="PDBsum" id="4K33"/>
<dbReference type="ProteinModelPortal" id="P22607"/>
<dbReference type="SMR" id="P22607"/>
<dbReference type="BioGrid" id="108552">
<property type="interactions" value="43"/>
</dbReference>
<dbReference type="DIP" id="DIP-4016N"/>
<dbReference type="IntAct" id="P22607">
<property type="interactions" value="27"/>
</dbReference>
<dbReference type="MINT" id="MINT-1034697"/>
<dbReference type="STRING" id="9606.ENSP00000339824"/>
<dbReference type="BindingDB" id="P22607"/>
<dbReference type="ChEMBL" id="CHEMBL2742"/>
<dbReference type="DrugBank" id="DB09078">
<property type="generic name" value="Lenvatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB09079">
<property type="generic name" value="Nintedanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB00039">
<property type="generic name" value="Palifermin"/>
</dbReference>
<dbReference type="DrugBank" id="DB06589">
<property type="generic name" value="Pazopanib"/>
</dbReference>
<dbReference type="DrugBank" id="DB08901">
<property type="generic name" value="Ponatinib"/>
</dbReference>
<dbReference type="DrugBank" id="DB05014">
<property type="generic name" value="XL999"/>
</dbReference>
<dbReference type="GuidetoPHARMACOLOGY" id="1810"/>
<dbReference type="iPTMnet" id="P22607"/>
<dbReference type="PhosphoSitePlus" id="P22607"/>
<dbReference type="BioMuta" id="FGFR3"/>
<dbReference type="DMDM" id="120050"/>
<dbReference type="PaxDb" id="P22607"/>
<dbReference type="PeptideAtlas" id="P22607"/>
<dbReference type="PRIDE" id="P22607"/>
<dbReference type="DNASU" id="2261"/>
<dbReference type="Ensembl" id="ENST00000260795">
<molecule id="P22607-1"/>
<property type="protein sequence ID" value="ENSP00000260795"/>
<property type="gene ID" value="ENSG00000068078"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000340107">
<molecule id="P22607-2"/>
<property type="protein sequence ID" value="ENSP00000339824"/>
<property type="gene ID" value="ENSG00000068078"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000352904">
<molecule id="P22607-3"/>
<property type="protein sequence ID" value="ENSP00000231803"/>
<property type="gene ID" value="ENSG00000068078"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000412135">
<molecule id="P22607-3"/>
<property type="protein sequence ID" value="ENSP00000412903"/>
<property type="gene ID" value="ENSG00000068078"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000440486">
<molecule id="P22607-1"/>
<property type="protein sequence ID" value="ENSP00000414914"/>
<property type="gene ID" value="ENSG00000068078"/>
</dbReference>
<dbReference type="GeneID" id="2261"/>
<dbReference type="KEGG" id="hsa:2261"/>
<dbReference type="UCSC" id="uc003gdr.3">
<molecule id="P22607-1"/>
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="2261"/>
<dbReference type="DisGeNET" id="2261"/>
<dbReference type="GeneCards" id="FGFR3"/>
<dbReference type="GeneReviews" id="FGFR3"/>
<dbReference type="HGNC" id="HGNC:3690">
<property type="gene designation" value="FGFR3"/>
</dbReference>
<dbReference type="HPA" id="CAB004231"/>
<dbReference type="HPA" id="HPA067204"/>
<dbReference type="MalaCards" id="FGFR3"/>
<dbReference type="MIM" id="100800">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="109800">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="134934">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="146000">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="149730">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="162900">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="182000">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="187600">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="187601">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="254500">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="273300">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="602849">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="603956">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="610474">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="612247">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="616482">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P22607"/>
<dbReference type="OpenTargets" id="ENSG00000068078"/>
<dbReference type="Orphanet" id="15">
<property type="disease" value="Achondroplasia"/>
</dbReference>
<dbReference type="Orphanet" id="85164">
<property type="disease" value="Camptodactyly - tall stature - scoliosis - hearing loss"/>
</dbReference>
<dbReference type="Orphanet" id="93262">
<property type="disease" value="Crouzon syndrome - acanthosis nigricans"/>
</dbReference>
<dbReference type="Orphanet" id="251579">
<property type="disease" value="Giant cell glioblastoma"/>
</dbReference>
<dbReference type="Orphanet" id="251576">
<property type="disease" value="Gliosarcoma"/>
</dbReference>
<dbReference type="Orphanet" id="429">
<property type="disease" value="Hypochondroplasia"/>
</dbReference>
<dbReference type="Orphanet" id="35099">
<property type="disease" value="Isolated brachycephaly"/>
</dbReference>
<dbReference type="Orphanet" id="35098">
<property type="disease" value="Isolated plagiocephaly"/>
</dbReference>
<dbReference type="Orphanet" id="2363">
<property type="disease" value="Lacrimoauriculodentodigital syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="53271">
<property type="disease" value="Muenke syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="794">
<property type="disease" value="Saethre-Chotzen syndrome"/>
</dbReference>
<dbReference type="Orphanet" id="85165">
<property type="disease" value="Severe achondroplasia - developmental delay - acanthosis nigricans"/>
</dbReference>
<dbReference type="Orphanet" id="1860">
<property type="disease" value="Thanatophoric dysplasia type 1"/>
</dbReference>
<dbReference type="Orphanet" id="93274">
<property type="disease" value="Thanatophoric dysplasia type 2"/>
</dbReference>
<dbReference type="PharmGKB" id="PA28129"/>
<dbReference type="eggNOG" id="KOG0200">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG0515">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00760000118923"/>
<dbReference type="HOGENOM" id="HOG000263410"/>
<dbReference type="HOVERGEN" id="HBG000345"/>
<dbReference type="InParanoid" id="P22607"/>
<dbReference type="KO" id="K05094"/>
<dbReference type="OMA" id="SFDTCKP"/>
<dbReference type="OrthoDB" id="EOG091G0CQZ"/>
<dbReference type="PhylomeDB" id="P22607"/>
<dbReference type="TreeFam" id="TF316307"/>
<dbReference type="BRENDA" id="2.7.10.1">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-109704">
<property type="pathway name" value="PI3K Cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1257604">
<property type="pathway name" value="PIP3 activates AKT signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-1839130">
<property type="pathway name" value="Signaling by activated point mutants of FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-190371">
<property type="pathway name" value="FGFR3b ligand binding and activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-190372">
<property type="pathway name" value="FGFR3c ligand binding and activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2033514">
<property type="pathway name" value="FGFR3 mutant receptor activation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2033515">
<property type="pathway name" value="t(4;14) translocations of FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-2219530">
<property type="pathway name" value="Constitutive Signaling by Aberrant PI3K in Cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654227">
<property type="pathway name" value="Phospholipase C-mediated cascade, FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654704">
<property type="pathway name" value="SHC-mediated cascade:FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654706">
<property type="pathway name" value="FRS-mediated FGFR3 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654710">
<property type="pathway name" value="PI-3K cascade:FGFR3"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5654732">
<property type="pathway name" value="Negative regulation of FGFR3 signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-5673001">
<property type="pathway name" value="RAF/MAP kinase cascade"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-6811558">
<property type="pathway name" value="PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8853334">
<property type="pathway name" value="Signaling by FGFR3 fusions in cancer"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8853338">
<property type="pathway name" value="Signaling by FGFR3 point mutants in cancer"/>
</dbReference>
<dbReference type="SignaLink" id="P22607"/>
<dbReference type="SIGNOR" id="P22607"/>
<dbReference type="ChiTaRS" id="FGFR3">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P22607"/>
<dbReference type="GeneWiki" id="Fibroblast_growth_factor_receptor_3"/>
<dbReference type="GenomeRNAi" id="2261"/>
<dbReference type="PRO" id="PR:P22607"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 4"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000068078"/>
<dbReference type="CleanEx" id="HS_FGFR3"/>
<dbReference type="ExpressionAtlas" id="P22607">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P22607">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0009986">
<property type="term" value="C:cell surface"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005887">
<property type="term" value="C:integral component of plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030133">
<property type="term" value="C:transport vesicle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016303">
<property type="term" value="F:1-phosphatidylinositol-3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005524">
<property type="term" value="F:ATP binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0017134">
<property type="term" value="F:fibroblast growth factor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005007">
<property type="term" value="F:fibroblast growth factor-activated receptor activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046934">
<property type="term" value="F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0004713">
<property type="term" value="F:protein tyrosine kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005088">
<property type="term" value="F:Ras guanyl-nucleotide exchange factor activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0070977">
<property type="term" value="P:bone maturation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030282">
<property type="term" value="P:bone mineralization"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0060349">
<property type="term" value="P:bone morphogenesis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007267">
<property type="term" value="P:cell-cell signaling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0002062">
<property type="term" value="P:chondrocyte differentiation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0035988">
<property type="term" value="P:chondrocyte proliferation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0003416">
<property type="term" value="P:endochondral bone growth"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001958">
<property type="term" value="P:endochondral ossification"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902178">
<property type="term" value="P:fibroblast growth factor receptor apoptotic signaling pathway"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008543">
<property type="term" value="P:fibroblast growth factor receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007259">
<property type="term" value="P:JAK-STAT cascade"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0000165">
<property type="term" value="P:MAPK cascade"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0048640">
<property type="term" value="P:negative regulation of developmental growth"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0018108">
<property type="term" value="P:peptidyl-tyrosine phosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048015">
<property type="term" value="P:phosphatidylinositol-mediated signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0008284">
<property type="term" value="P:positive regulation of cell proliferation"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043410">
<property type="term" value="P:positive regulation of MAPK cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043552">
<property type="term" value="P:positive regulation of phosphatidylinositol 3-kinase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010518">
<property type="term" value="P:positive regulation of phospholipase activity"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042511">
<property type="term" value="P:positive regulation of tyrosine phosphorylation of Stat1 protein"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042517">
<property type="term" value="P:positive regulation of tyrosine phosphorylation of Stat3 protein"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046777">
<property type="term" value="P:protein autophosphorylation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0014066">
<property type="term" value="P:regulation of phosphatidylinositol 3-kinase signaling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0001501">
<property type="term" value="P:skeletal system development"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="Gene3D" id="2.60.40.10">
<property type="match status" value="4"/>
</dbReference>
<dbReference type="InterPro" id="IPR028176">
<property type="entry name" value="FGF_rcpt_3"/>
</dbReference>
<dbReference type="InterPro" id="IPR016248">
<property type="entry name" value="FGF_rcpt_fam"/>
</dbReference>
<dbReference type="InterPro" id="IPR007110">
<property type="entry name" value="Ig-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR013783">
<property type="entry name" value="Ig-like_fold"/>
</dbReference>
<dbReference type="InterPro" id="IPR013098">
<property type="entry name" value="Ig_I-set"/>
</dbReference>
<dbReference type="InterPro" id="IPR003599">
<property type="entry name" value="Ig_sub"/>
</dbReference>
<dbReference type="InterPro" id="IPR003598">
<property type="entry name" value="Ig_sub2"/>
</dbReference>
<dbReference type="InterPro" id="IPR011009">
<property type="entry name" value="Kinase-like_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR000719">
<property type="entry name" value="Prot_kinase_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR017441">
<property type="entry name" value="Protein_kinase_ATP_BS"/>
</dbReference>
<dbReference type="InterPro" id="IPR001245">
<property type="entry name" value="Ser-Thr/Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="InterPro" id="IPR008266">
<property type="entry name" value="Tyr_kinase_AS"/>
</dbReference>
<dbReference type="InterPro" id="IPR020635">
<property type="entry name" value="Tyr_kinase_cat_dom"/>
</dbReference>
<dbReference type="PANTHER" id="PTHR24416:SF401">
<property type="entry name" value="PTHR24416:SF401"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07679">
<property type="entry name" value="I-set"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="Pfam" id="PF07714">
<property type="entry name" value="Pkinase_Tyr"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF000628">
<property type="entry name" value="FGFR"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PRINTS" id="PR00109">
<property type="entry name" value="TYRKINASE"/>
</dbReference>
<dbReference type="SMART" id="SM00409">
<property type="entry name" value="IG"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00408">
<property type="entry name" value="IGc2"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SMART" id="SM00219">
<property type="entry name" value="TyrKc"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF48726">
<property type="entry name" value="SSF48726"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="SUPFAM" id="SSF56112">
<property type="entry name" value="SSF56112"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50835">
<property type="entry name" value="IG_LIKE"/>
<property type="match status" value="3"/>
</dbReference>
<dbReference type="PROSITE" id="PS00107">
<property type="entry name" value="PROTEIN_KINASE_ATP"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS50011">
<property type="entry name" value="PROTEIN_KINASE_DOM"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PROSITE" id="PS00109">
<property type="entry name" value="PROTEIN_KINASE_TYR"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0025">Alternative splicing</keyword>
<keyword id="KW-0053">Apoptosis</keyword>
<keyword id="KW-0067">ATP-binding</keyword>
<keyword id="KW-1003">Cell membrane</keyword>
<keyword id="KW-0160">Chromosomal rearrangement</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0989">Craniosynostosis</keyword>
<keyword id="KW-0968">Cytoplasmic vesicle</keyword>
<keyword id="KW-0209">Deafness</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-1015">Disulfide bond</keyword>
<keyword id="KW-0242">Dwarfism</keyword>
<keyword id="KW-0038">Ectodermal dysplasia</keyword>
<keyword id="KW-0256">Endoplasmic reticulum</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0393">Immunoglobulin domain</keyword>
<keyword id="KW-0418">Kinase</keyword>
<keyword id="KW-0953">Lacrimo-auriculo-dento-digital syndrome</keyword>
<keyword id="KW-0472">Membrane</keyword>
<keyword id="KW-0547">Nucleotide-binding</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-0675">Receptor</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0964">Secreted</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0808">Transferase</keyword>
<keyword id="KW-0812">Transmembrane</keyword>
<keyword id="KW-1133">Transmembrane helix</keyword>
<keyword id="KW-0829">Tyrosine-protein kinase</keyword>
<keyword id="KW-0832">Ubl conjugation</keyword>
<feature type="signal peptide">
<location>
<begin position="1"/>
<end position="22"/>
</location>
</feature>
<feature type="chain" description="Fibroblast growth factor receptor 3" id="PRO_0000016785">
<location>
<begin position="23"/>
<end position="806"/>
</location>
</feature>
<feature type="topological domain" description="Extracellular" evidence="6">
<location>
<begin position="23"/>
<end position="375"/>
</location>
</feature>
<feature type="transmembrane region" description="Helical" evidence="6">
<location>
<begin position="376"/>
<end position="396"/>
</location>
</feature>
<feature type="topological domain" description="Cytoplasmic" evidence="6">
<location>
<begin position="397"/>
<end position="806"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 1">
<location>
<begin position="24"/>
<end position="126"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 2">
<location>
<begin position="151"/>
<end position="244"/>
</location>
</feature>
<feature type="domain" description="Ig-like C2-type 3">
<location>
<begin position="253"/>
<end position="355"/>
</location>
</feature>
<feature type="domain" description="Protein kinase" evidence="8">
<location>
<begin position="472"/>
<end position="761"/>
</location>
</feature>
<feature type="nucleotide phosphate-binding region" description="ATP" evidence="8">
<location>
<begin position="478"/>
<end position="486"/>
</location>
</feature>
<feature type="active site" description="Proton acceptor" evidence="8 9">
<location>
<position position="617"/>
</location>
</feature>
<feature type="binding site" description="ATP" evidence="8">
<location>
<position position="508"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location>
<position position="444"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine" evidence="5">
<location>
<position position="445"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="67">
<location>
<position position="647"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="67">
<location>
<position position="648"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="18">
<location>
<position position="724"/>
</location>
</feature>
<feature type="modified residue" description="Phosphotyrosine; by autocatalysis" evidence="43">
<location>
<position position="760"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="98"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="225"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="262"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="294"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="315"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (GlcNAc...) asparagine" evidence="6">
<location>
<position position="328"/>
</location>
</feature>
<feature type="disulfide bond" evidence="7">
<location>
<begin position="61"/>
<end position="109"/>
</location>
</feature>
<feature type="disulfide bond" evidence="7">
<location>
<begin position="176"/>
<end position="228"/>
</location>
</feature>
<feature type="disulfide bond" evidence="7">
<location>
<begin position="275"/>
<end position="339"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 3." id="VSP_002989" evidence="63">
<location>
<begin position="311"/>
<end position="422"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 2." id="VSP_002988" evidence="64">
<original>TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLP</original>
<variation>SWISESVEADVRLRLANVSERDGGEYLCRATNFIGVAEKAFWLSVHGPRA</variation>
<location>
<begin position="311"/>
<end position="358"/>
</location>
</feature>
<feature type="splice variant" description="In isoform 4." id="VSP_040945" evidence="65">
<original>GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT</original>
<variation>LVLWGPALGDLHAGGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVHDHAGVLACRALPEAHLQAAGGGPGPCPYRDVHRRVPGPVGAFRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADVKGHWSPTM</variation>
<location>
<begin position="654"/>
<end position="806"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs2305178." id="VAR_022167" evidence="62">
<original>G</original>
<variation>R</variation>
<location>
<position position="65"/>
</location>
</feature>
<feature type="sequence variant" description="In a lung adenocarcinoma sample; somatic mutation." id="VAR_042207" evidence="37">
<original>T</original>
<variation>S</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="sequence variant" description="In a colorectal adenocarcinoma sample; somatic mutation." id="VAR_042208" evidence="37">
<original>C</original>
<variation>R</variation>
<location>
<position position="228"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB, BLC, keratinocytic non-epidermolytic nevus and TD1; severe and lethal; also found as somatic mutation in one patient with multiple myeloma; constitutive dimerization and kinase activation; dbSNP:rs121913482." id="VAR_004148" evidence="12 13 21 28 33 38 48 55">
<original>R</original>
<variation>C</variation>
<location>
<position position="248"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB, BLC, cervical cancer and TD1; dbSNP:rs121913483." id="VAR_004149" evidence="12 13 28 51 55">
<original>S</original>
<variation>C</variation>
<location>
<position position="249"/>
</location>
</feature>
<feature type="sequence variant" description="In MNKS; also some individuals with autosomal dominant congenital sensorineural deafness without craniosynostosis; dbSNP:rs4647924." id="VAR_004150" evidence="23 56 59 61">
<original>P</original>
<variation>R</variation>
<location>
<position position="250"/>
</location>
</feature>
<feature type="sequence variant" description="In colorectal cancer; dbSNP:rs121913111." id="VAR_018388" evidence="20">
<original>E</original>
<variation>K</variation>
<location>
<position position="322"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_042209" evidence="37">
<original>T</original>
<variation>M</variation>
<location>
<position position="338"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB, BLC, keratinocytic non-epidermolytic nevus and TD1; dbSNP:rs121913479." id="VAR_004151" evidence="13 28 33 55 60">
<original>G</original>
<variation>C</variation>
<location>
<position position="370"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB and TD1; dbSNP:rs121913484." id="VAR_004152" evidence="28 48">
<original>S</original>
<variation>C</variation>
<location>
<position position="371"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB and TD1; disulfide-linked dimer with constitutive kinase activation; dbSNP:rs121913485." id="VAR_004153" evidence="12 28 38 55 57">
<original>Y</original>
<variation>C</variation>
<location>
<position position="373"/>
</location>
</feature>
<feature type="sequence variant" description="In ACH; dbSNP:rs75790268." id="VAR_004154" evidence="47">
<original>G</original>
<variation>C</variation>
<location>
<position position="375"/>
</location>
</feature>
<feature type="sequence variant" description="In keratinocytic non-epidermolytic nevus and ACH; very common mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs28931614." id="VAR_004155" evidence="14 24 33 39 49 50 52">
<original>G</original>
<variation>R</variation>
<location>
<position position="380"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs17881656." id="VAR_022168" evidence="37 62">
<original>F</original>
<variation>L</variation>
<location>
<position position="384"/>
</location>
</feature>
<feature type="sequence variant" description="In CAN; dbSNP:rs28931615." id="VAR_004156" evidence="41 45">
<original>A</original>
<variation>E</variation>
<location>
<position position="391"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs17884368." id="VAR_022169" evidence="62">
<original>A</original>
<variation>T</variation>
<location>
<position position="441"/>
</location>
</feature>
<feature type="sequence variant" description="In LADDS; dbSNP:rs121913112." id="VAR_029887" evidence="30">
<original>D</original>
<variation>N</variation>
<location>
<position position="513"/>
</location>
</feature>
<feature type="sequence variant" description="In hypochondroplasia; dbSNP:rs80053154." id="VAR_004157" evidence="11">
<original>I</original>
<variation>V</variation>
<location>
<position position="538"/>
</location>
</feature>
<feature type="sequence variant" description="In hypochondroplasia; dbSNP:rs28933068." id="VAR_004158" evidence="46">
<original>N</original>
<variation>K</variation>
<location>
<position position="540"/>
</location>
</feature>
<feature type="sequence variant" description="In hypochondroplasia; mild; dbSNP:rs77722678." id="VAR_018389" evidence="16 25">
<original>N</original>
<variation>S</variation>
<location>
<position position="540"/>
</location>
</feature>
<feature type="sequence variant" description="In hypochondroplasia; dbSNP:rs77722678." id="VAR_004159" evidence="58">
<original>N</original>
<variation>T</variation>
<location>
<position position="540"/>
</location>
</feature>
<feature type="sequence variant" description="In CATSHLS; dbSNP:rs121913113." id="VAR_029108" evidence="34">
<original>R</original>
<variation>H</variation>
<location>
<position position="621"/>
</location>
</feature>
<feature type="sequence variant" id="VAR_042210" evidence="37">
<original>D</original>
<variation>N</variation>
<location>
<position position="646"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB, TD2, TGCT and BLC; bladder transitional cell carcinoma; somatic mutation; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs78311289." id="VAR_004160" evidence="13 18 24 26 28 35 37 39 44 48 54 57">
<original>K</original>
<variation>E</variation>
<location>
<position position="650"/>
</location>
</feature>
<feature type="sequence variant" description="In KERSEB, ACH, TD1 and SADDAN; constitutively activated kinase with impaired internalization and degradation, resulting in prolonged FGFR3 signaling; dbSNP:rs121913105." id="VAR_004161" evidence="10 15 28 38 39 57">
<original>K</original>
<variation>M</variation>
<location>
<position position="650"/>
</location>
</feature>
<feature type="sequence variant" description="In hypochondroplasia and BLC; in hypochondroplasia the form is milder than that seen in individuals with the K-540 or M-650 mutations; constitutively activated kinase; dbSNP:rs78311289." id="VAR_018390" evidence="17 19 54">
<original>K</original>
<variation>Q</variation>
<location>
<position position="650"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs17882190." id="VAR_022170" evidence="62">
<original>A</original>
<variation>T</variation>
<location>
<position position="717"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs17880763." id="VAR_022171" evidence="62">
<original>I</original>
<variation>F</variation>
<location>
<position position="726"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of kinase activity. Abolishes ubiquitination." evidence="24 29">
<original>K</original>
<variation>A</variation>
<location>
<position position="508"/>
</location>
</feature>
<feature type="mutagenesis site" description="Minor effect on kinase activity." evidence="18">
<original>Y</original>
<variation>F</variation>
<location>
<position position="577"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively activated kinase.">
<original>K</original>
<variation>D</variation>
<location>
<position position="650"/>
</location>
</feature>
<feature type="mutagenesis site" description="Constitutively activated kinase.">
<original>K</original>
<variation>L</variation>
<location>
<position position="650"/>
</location>
</feature>
<feature type="mutagenesis site" description="Strongly reduced kinase activity. Strongly reduced mitogen activity." evidence="18">
<original>Y</original>
<variation>F</variation>
<location>
<position position="724"/>
</location>
</feature>
<feature type="mutagenesis site" description="Minor effect on kinase activity." evidence="18">
<original>Y</original>
<variation>F</variation>
<location>
<position position="760"/>
</location>
</feature>
<feature type="mutagenesis site" description="Minor effect on kinase activity. Increased mitogen activity." evidence="18">
<original>Y</original>
<variation>F</variation>
<location>
<position position="770"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 7; AAA58470." ref="7" evidence="66">
<original>L</original>
<variation>V</variation>
<location>
<position position="395"/>
</location>
</feature>
<feature type="sequence conflict" description="In Ref. 3; BAD92678." ref="3" evidence="66">
<original>R</original>
<variation>RQ</variation>
<location>
<position position="421"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="163"/>
<end position="167"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="172"/>
<end position="175"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="185"/>
<end position="187"/>
</location>
</feature>
<feature type="turn" evidence="1">
<location>
<begin position="208"/>
<end position="211"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="212"/>
<end position="215"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="220"/>
<end position="222"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="226"/>
<end position="232"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="235"/>
<end position="246"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="263"/>
<end position="268"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="271"/>
<end position="273"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="283"/>
<end position="289"/>
</location>
</feature>
<feature type="helix" evidence="1">
<location>
<begin position="293"/>
<end position="295"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="302"/>
<end position="304"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="324"/>
<end position="326"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="335"/>
<end position="345"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="348"/>
<end position="357"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="369"/>
<end position="372"/>
</location>
</feature>
<feature type="helix" evidence="2">
<location>
<begin position="374"/>
<end position="398"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="463"/>
<end position="465"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="469"/>
<end position="471"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="472"/>
<end position="480"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="482"/>
<end position="496"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="503"/>
<end position="510"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="516"/>
<end position="532"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="541"/>
<end position="545"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="547"/>
<end position="550"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="552"/>
<end position="556"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="563"/>
<end position="568"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="591"/>
<end position="610"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="620"/>
<end position="622"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="623"/>
<end position="625"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="631"/>
<end position="633"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="646"/>
<end position="649"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="658"/>
<end position="660"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="663"/>
<end position="668"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="673"/>
<end position="688"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="700"/>
<end position="708"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="721"/>
<end position="730"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="735"/>
<end position="737"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="741"/>
<end position="753"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1RY7"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2LZL"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4K33"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000250"/>
<evidence key="5" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="Q61851"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000255"/>
<evidence key="7" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00114"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU00159"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000255">
<source>
<dbReference type="PROSITE-ProRule" id="PRU10028"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10053006"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10215410"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10360402"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10471491"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10611230"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10671061"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10777366"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11055896"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11294897"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11314002"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11325814"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11529856"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11703096"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11746040"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12297284"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12707965"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14534538"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14732692"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="15772091"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16410555"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16501574"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16597617"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1664411"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16841094"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17033969"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17145761"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17311277"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17344846"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17509076"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17561467"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17623664"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17935505"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19088846"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19286672"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19855393"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7493034"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7670477"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7758520"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7773297"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7847369"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8078586"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8589699"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8599935"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8663044"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8754806"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8845844"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9042914"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9207791"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9452043"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9525367"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9790257"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9950359"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source ref="4"/>
</evidence>
<evidence key="63" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="11703096"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="7495869"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000303">
<source ref="3"/>
</evidence>
<evidence key="66" type="ECO:0000305"/>
<evidence key="67" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="8754806"/>
</source>
</evidence>
<sequence length="806" mass="87710" checksum="BC5EA75EA46F447E" modified="1991-08-01" version="1" precursor="true">
MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS
CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH
FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG
NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT
YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP
DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLPAE
EELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRFPLK
RQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKPLGE
GCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIIN
LLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQ
VARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKW
MAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCT
HDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSS
SSSGDDSVFAHDLLPPAPPSSGGSRT
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>